While multiple advantageous aspects of the metabolic reprogramming for NRF2-addicted cancer cells have been described, metabolic liabilities resulting from NRF2-dependent reprogramming have also been investigated
Han D, Handelman G, Marcocci L, et al
In Phase 2/3 clinical trials, participants lost an average of 24-29% of body weight at the highest doses (8-12 mg) over 48-68 weeks
HGF protein benefits are largely dependent on the way of administration, mostly due to HGF short half-life and poor accessibility to the BBB
The combination may increase the risk of gastrointestinal side effectsparticularly diarrhoea, nausea, and abdominal discomfortwhich are common to both substances
10.1016/S0140-6736(12)60691-6